The goal of this retrospective observational study is to describe the incidence and outcome of patients diagnosed with acute mesenteric ischemia (AMI) in the Västra Götaland region of Sweden between 2000-2023. The main questions it aims to answer are: * What was the observed incidence and outcome, and how did it change during the time period? * How did socioeconomic factors influence incidence and outcome of AMI? * What main surgical approaches were selected for these patients? * What was the distribution of anticoagulant use in the cohort, and what effect did the introduction of new oral anticoagulants (NOAC) have on incidence and mortality in AMI? * What was the prevalence of Short Bowel Syndrome (SBS) after surgical intervention? Participants were obtained from the regional diagnosis registry. Additional datapoints were obtained from the Swedish statistics bureau and pharmaceutical registers.
Study Type
OBSERVATIONAL
Enrollment
2,446
Sahlgrenska hospital/Östra hospital
Gothenburg, Västra Götaland County, Sweden
Sahlgrenska University Hospital
Gothenburg, Sweden
Incidence of acute mesenteric ischemia
Annual incidence rate of acute mesenteric ischemia per 100,000 person-years in the Västra Götaland region.
Time frame: Year 2000-2023
Mortality from acute mesenteric ischemia
All-cause mortality within up to 1 year of AMI diagnosis.
Time frame: 30 days, 90 days, 1 year.
Temporal trends in incidence and mortality
Change over time in incidence and mortality, including before and after introduction of non-vitamin K antagonist oral anticoagulants (NOACs).
Time frame: Year 2000-2023
Socioeconomic determinants of incidence and outcome
Association between SES indicators (income, education, immigration status, geographic distance to care) and risk of AMI or mortality.
Time frame: Year 2000-2023
Surgical management strategy
Proportion of patients undergoing bowel resection, revascularization (open or endovascular), or non-operative management.
Time frame: Year 2000-2023
Prevalence of Short Bowel Syndrome (SBS)
Number and percentage of patients developing SBS (ICD-10 K91.2 and K90.8) after AMI.
Time frame: Within 1 year of surgical intervention
Anticoagulant use patterns
Proportion of patients using vitamin-K antagonists, NOACs, antiplatelet therapy, or no anticoagulation; association with incidence and survival.
Time frame: At AMI diagnosis; trends from 2000-2023
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.